Protagonist Therapeutics (PTGX) Total Current Liabilities (2015 - 2026)

Protagonist Therapeutics has reported Total Current Liabilities for 12 years, with the latest figure at $34.5 million in Q1 2026.

• Quarterly Total Current Liabilities fell 1.6% year-over-year to $34.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $34.5 million (down 1.6% YoY) and the FY2025 annual result came in at $45.4 million, down 4.13% from the prior year.
• Total Current Liabilities slipped to $34.5 million in Q1 2026 per PTGX's latest filing, from $45.4 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $47.4 million in Q4 2024 and troughed at $21.3 million in Q4 2023.
• A 5-year average of $36.4 million and a median of $36.8 million in 2022 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2023 and 2024: Total Current Liabilities slumped 46.55% in 2023, then jumped 122.8% in 2024.
• Over 5 years, Total Current Liabilities stood at $31.2 million in 2022, then plunged by 31.77% to $21.3 million in 2023, then surged by 122.8% to $47.4 million in 2024, then slipped by 4.13% to $45.4 million in 2025, then declined by 23.97% to $34.5 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $34.5 million, $45.4 million, and $44.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.